EPHA2 and cancer: Flow cytometry analysis showed that ATG9A KO did not alter the expression of key phagocytosis checkpoints (MHC-I, PD-L1, CD24, CD47) or the CAR target EphA2 (Supplementary Fig. 2J), suggesting ATG9A regulates cancer cell susceptibility to macrophage killing through a specific and independent mechanism.